Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients ...

BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of ...

TAMPA, Fla., June 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported ...

-- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes -- PARSIPPANY, N.J., Nov. 04, 2024 (GLOBE ...

In Florida, more than 5 million adults are living with arthritis 1 – one of the highest rates in the nation. Of the various types of arthritis, the most common is osteoarthritis (OA), a degenerative ...

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment-- --PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world ...

Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).

The separate reimbursement for iovera° will pay up to an additional $255.85 when providers administer iovera° in ASC and HOPD settings, using a new C-code created for the iovera° system (C9809). This ...